Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | Buy → Underperform | BofA Securities | |
| 8/22/2024 | $24.00 | Buy | Needham |
| 8/9/2024 | Outperform → In-line | Imperial Capital | |
| 5/22/2024 | $16.00 → $20.00 | Buy → Neutral | Citigroup |
| 4/16/2024 | $17.00 → $15.00 | Buy → Hold | Jefferies |
| 4/10/2024 | $20.00 | Buy | Canaccord Genuity |
| 2/28/2024 | $16.00 | In-line → Outperform | Imperial Capital |
| 2/26/2024 | $10.00 | Market Perform | Leerink Partners |
BofA Securities downgraded Hims & Hers Health from Buy to Underperform
Needham initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $24.00
Imperial Capital downgraded Hims & Hers Health from Outperform to In-line
Hims & Hers Health, Inc. (NYSE:HIMS) saw a notable surge in its stock Tuesday possibly from continued momentum from yesterday. Here’s what you need to know. What To Know: The company is scheduled to release its second-quarter earnings report on August 5th, after market close. The company's estimated earnings per share (EPS) for the quarter stands at 4 cents, with revenue projections at approximately $299.9 million What Else: In a significant development for the pharmaceutical industry, Novo Nordisk's weight-loss drug Wegovy has received expanded approval in the UK. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has now approved Wegovy not just for obesity treatment b
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday. Shares of Danaher Corporation (NYSE:DHR) rose sharply during Tuesday's session after the company reported better-than-expected second quarter earnings. Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from Benzinga Pro. Danaher shares gained 7.4% to $269.35 on Tuesday. Here are some other big stocks recording gains in today’s session. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares jumped 16% to $24.81 af
- Bloomberg
Continuing to strengthen its comprehensive weight loss offerings, Hims & Hers' addition of daily meal replacement bars and shakes is the company's latest step in helping its customers reach – and maintain – their health and wellness goals Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that Hims & Hers customers will now be able to supplement their treatment plan with daily meal replacement bars and shakes to support them on their comprehensive weight loss journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121849741/en/To help its customers stay on top of
Former FDA deputy commissioner and former Pfizer & Hillrom quality executive join Hims & Hers, deepening the leadership that drives the company's high standard of quality and safety Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality,
Hims & Hers introduces a GLP-1 Supply Tracker to help more individuals advocate for accessible healthcare Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals can be a part of advocating for better access to the medications they need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113063032/en/Hims & Hers introduces a GLP-1 Supply Tracker to help more individuals advocate for accessible healthcare. (Graphic: Business
Former FDA deputy commissioner and former Pfizer & Hillrom quality executive join Hims & Hers, deepening the leadership that drives the company's high standard of quality and safety Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality,
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024 Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Improving momentum in both the Hims and Hers brands delivered another strong qu
Hims & Hers Health, Inc. ((", Hims &, Hers", , NYSE:HIMS), the leading health and wellness platform, today announced that it will report third quarter financial results after the market closes on Monday, November 4, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to
Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredibl
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)